11,183 Shares in Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) Acquired by Impact Partnership Wealth LLC

Impact Partnership Wealth LLC bought a new position in shares of Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The firm bought 11,183 shares of the biotechnology company’s stock, valued at approximately $83,000.

Several other hedge funds have also recently added to or reduced their stakes in the company. Perceptive Advisors LLC raised its holdings in Iovance Biotherapeutics by 34.6% during the 2nd quarter. Perceptive Advisors LLC now owns 25,933,142 shares of the biotechnology company’s stock worth $207,984,000 after purchasing an additional 6,660,151 shares during the last quarter. State Street Corp raised its holdings in Iovance Biotherapeutics by 4.6% during the 3rd quarter. State Street Corp now owns 13,201,978 shares of the biotechnology company’s stock worth $123,967,000 after purchasing an additional 576,801 shares during the last quarter. Principal Financial Group Inc. raised its holdings in Iovance Biotherapeutics by 59.0% during the 3rd quarter. Principal Financial Group Inc. now owns 4,033,184 shares of the biotechnology company’s stock worth $37,872,000 after purchasing an additional 1,496,941 shares during the last quarter. Assenagon Asset Management S.A. bought a new position in Iovance Biotherapeutics during the 4th quarter worth approximately $12,927,000. Finally, Rice Hall James & Associates LLC raised its holdings in Iovance Biotherapeutics by 2.6% during the 3rd quarter. Rice Hall James & Associates LLC now owns 1,679,157 shares of the biotechnology company’s stock worth $15,767,000 after purchasing an additional 43,132 shares during the last quarter. Institutional investors own 77.03% of the company’s stock.

Iovance Biotherapeutics Trading Up 1.0 %

NASDAQ IOVA opened at $6.25 on Friday. The company has a fifty day simple moving average of $7.63 and a 200 day simple moving average of $9.10. Iovance Biotherapeutics, Inc. has a 12-month low of $5.57 and a 12-month high of $18.33. The company has a market cap of $1.90 billion, a P/E ratio of -4.19 and a beta of 0.57.

Iovance Biotherapeutics (NASDAQ:IOVA) last posted its quarterly earnings results on Thursday, November 7th. The biotechnology company reported ($0.28) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.31) by $0.03. Iovance Biotherapeutics had a negative net margin of 451.25% and a negative return on equity of 58.43%. The business had revenue of $58.56 million during the quarter, compared to the consensus estimate of $53.54 million. During the same quarter last year, the firm posted ($0.46) EPS. Sell-side analysts predict that Iovance Biotherapeutics, Inc. will post -1.23 EPS for the current year.

Analysts Set New Price Targets

IOVA has been the subject of several analyst reports. HC Wainwright restated a “buy” rating and set a $32.00 price target on shares of Iovance Biotherapeutics in a report on Wednesday, November 6th. UBS Group started coverage on shares of Iovance Biotherapeutics in a research note on Thursday, October 24th. They issued a “buy” rating and a $17.00 price objective for the company. One analyst has rated the stock with a sell rating, one has issued a hold rating and seven have assigned a buy rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $23.00.

Insider Activity at Iovance Biotherapeutics

In related news, Director Ryan D. Maynard sold 50,000 shares of Iovance Biotherapeutics stock in a transaction on Tuesday, November 12th. The shares were sold at an average price of $10.06, for a total value of $503,000.00. Following the completion of the sale, the director now owns 7,500 shares of the company’s stock, valued at approximately $75,450. This trade represents a 86.96 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. 12.10% of the stock is currently owned by insiders.

About Iovance Biotherapeutics

Iovance Biotherapeutics, Inc, a commercial-stage biotechnology company, develops and commercializes cell therapies using autologous tumor infiltrating lymphocyte for the treatment of metastatic melanoma and other solid tumor cancers in the United States. The company offers Amtagvi, a tumor-derived autologous T cell immunotherapy used to treat adult patients with unresectable or metastatic melanoma; and Proleukin, an interleukin-2 product for the treatment of patients with metastatic renal cell carcinoma.